KRAS inhibitor(BlossomHill Therapeutics)

Sotorasib was the frst approved KRAS inhibitor granted marketing authorisation by the US Food and Drug administration (FDA) by use of the accelerated approval pathway for patients with advanced non-small-cell lung cancer (NSCLC) with the KRAS G12C mutation.This was acknowledged by the FDA and we believe it also raises the potential that not only does the drug not extend survival, but it could potentially worsen it.